TY - JOUR
T1 - A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG)
T2 - Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer
AU - The Breast Cancer Therapy Expert Group (BCTEG)
AU - Mahtani, Reshma
AU - Holmes, Frankie Ann
AU - Badve, Sunil
AU - Caldera, Humberto
AU - Coleman, Robert
AU - Mamounas, Eleftherios
AU - Kalinsky, Kevin
AU - Kittaneh, Muaiad
AU - Lower, Elyse
AU - Pegram, Mark
AU - Press, Michael F.
AU - Rugo, Hope S.
AU - Schwartzberg, Lee
AU - Vogel, Charles
N1 - Funding Information:
This manuscript was funded by unrestricted educational grants provided by Puma Biotechnology , Daiichi-Sankyo , and Caris Life Sciences , with additional support from Total Health Conferencing . The faculty was compensated by Total Health Conferencing for their participation. Independent medical writing support was provided by Sciavo TECH Research and Consultancy Services, Inc. and funded by Total Health Conferencing .
PY - 2020/6
Y1 - 2020/6
N2 - Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and neratinib), all of which have dramatically changed the prognosis for this aggressive subtype of breast cancer. A roundtable meeting of the Breast Cancer Therapy Expert Group (BCTEG) was convened in March 2018 in an effort to discuss and clarify, from the perspective of the practicing community oncologist, recent developments in the diagnosis and treatment of HER2-positive (HER2+) breast cancer. Members of the group selected 4 key topics for discussion prior to the meeting, including diagnosis of HER2+ disease, and its treatment in the neoadjuvant, adjuvant, and metastatic settings. Approved testing methods, such as immunohistochemistry and fluorescence in situ hybridization, are used to demonstrate overexpression and/or amplification of HER2 in breast tumors, and established clinical guidelines are used to appropriately define treatment plans for patients with HER2+ disease. The panel acknowledges a range of treatment options now available for treatment of HER2+ breast cancer in the neoadjuvant, adjuvant, and advanced/metastatic settings, although it is noted that many controversies remain, including the optimal sequence of therapies, the most appropriate treatment(s) for subsets of patients with HER2+ disease (eg, hormone receptor-negative or -positive/HER2+), and uncertainties surrounding the diagnosis and definition of HER2+ disease. The current report summarizes the discussion of the BCTEG panel on this topic.
AB - Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyrosine kinase inhibitor (TKI) drugs (eg, lapatinib and neratinib), all of which have dramatically changed the prognosis for this aggressive subtype of breast cancer. A roundtable meeting of the Breast Cancer Therapy Expert Group (BCTEG) was convened in March 2018 in an effort to discuss and clarify, from the perspective of the practicing community oncologist, recent developments in the diagnosis and treatment of HER2-positive (HER2+) breast cancer. Members of the group selected 4 key topics for discussion prior to the meeting, including diagnosis of HER2+ disease, and its treatment in the neoadjuvant, adjuvant, and metastatic settings. Approved testing methods, such as immunohistochemistry and fluorescence in situ hybridization, are used to demonstrate overexpression and/or amplification of HER2 in breast tumors, and established clinical guidelines are used to appropriately define treatment plans for patients with HER2+ disease. The panel acknowledges a range of treatment options now available for treatment of HER2+ breast cancer in the neoadjuvant, adjuvant, and advanced/metastatic settings, although it is noted that many controversies remain, including the optimal sequence of therapies, the most appropriate treatment(s) for subsets of patients with HER2+ disease (eg, hormone receptor-negative or -positive/HER2+), and uncertainties surrounding the diagnosis and definition of HER2+ disease. The current report summarizes the discussion of the BCTEG panel on this topic.
KW - HER2
KW - Neratinib
KW - Pertuzumab
KW - T-DM1
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=85078769284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078769284&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2019.08.001
DO - 10.1016/j.clbc.2019.08.001
M3 - Review article
C2 - 32139271
AN - SCOPUS:85078769284
VL - 20
SP - e251-e260
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 3
ER -